Publications by authors named "S Ducastelle-Lepretre"
Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation.
View Article and Find Full Text PDFArticle Synopsis
- Nocardiosis is a serious infection that can occur after hematopoietic cell transplantation (HCT), and this study aimed to identify its risk factors and the impact of certain preventive treatments.
- A review of 64 cases of nocardiosis and 128 matched controls showed that factors like tacrolimus use, low lymphocyte counts, male sex, recent corticosteroid use, and previous CMV infections increased the risk of developing this infection.
- Conversely, patients on trimethoprim-sulfamethoxazole prophylaxis had a significantly lower risk of nocardiosis; however, those who did develop it had poorer survival rates compared to controls.
Background: Pulmonary mucormycosis (PM) is a life-threatening invasive mold infection. Diagnosis of mucormycosis is challenging and often delayed, resulting in higher mortality.
Research Question: Are the disease presentation of PM and contribution of diagnosis tools influenced by the patient's underlying condition?
Study Design And Methods: All PM cases from six French teaching hospitals between 2008 and 2019 were retrospectively reviewed.
Immune reconstitution after allogeneic-hematopoietic-stem-cell transplantation (allo-HSCT) is a complex and individual process. In this cross-sectional study, whole-blood (WB) immune functional assay (IFA) was used to characterize immune function by assessing immune-related gene/pathway alterations. The usefulness of this tool in the context of infection, 6 months after transplantation, was evaluated.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using FLAMSA-Bu is a treatment option for high-risk acute myeloid leukemia (AML) patients, particularly those who are refractory or have relapsed.
- A study of 165 patients showed that detectable minimal residual disease (MRD) before transplantation was linked to worse overall survival (OS) and higher relapse rates following the procedure.
- The findings highlight that pre-transplant MRD status is a crucial indicator of patient outcomes, with MRD negativity correlated to better survival and reduced relapse risk, while factors such as age and risk stratification did not significantly impact outcomes.